On January 6, 2023, the Food and Drug Administration (FDA) approved a new Alzheimer’s disease treatment that moderately slows cognitive decline in people with early-stage disease.
Although Leqembi (previously known by its scientific name lecanemab) is not a cure for Alzheimer’s, a large clinical trial published in November showed the treatment slowed the cognitive and functional decline of patients with early-stage Alzheimer’s by 27% relative to placebo. It is administered via an intravenous infusion every two weeks.
Leqembi , developed by Japanese pharmaceutical company Eisai, is expected to be in the mid-$20,000 range for a year’s treatment.
Under a long-standing partnership, Biogen, a Cambridge, Massachusetts-based biotech, will co-market the drug with Eisai.
Read the full article here.